Hamps Bio is engaged in the ethical marketing and distribution of pharmaceutical formulation products (“Pharma”) across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products (“FDFP” or “FMCG Division”) such as fruits, vegetables, herbs and flowers. They are recognized in the pharmaceutical industry under their own brand name “Hamps” and in freeze-dried and frozen food segment through their own brand.

Hamps Bio, an Fixed Price Issue amounting to ₹6.22 Crores, consisting entirely an Fresh Issue of 12.20 Lakh Shares. The subscription period for the Hamps Bio IPO opens on December 13, 2024, and closes on December 17, 2024. The allotment is expected to be finalized on or about Wednesday, December 18, 2024, and the shares will be listed on the BSE SME with a tentative listing date set on or about Friday, December 20, 2024.

 

 

 

 

 

 

 

 

The Share price of Hamps Bio IPO is set at ₹51 per equity share. The Market Capitalisation of the Hamps Bio Limited at IPO price of ₹51 per equity share will be ₹22.21 Crores. The lot size of the IPO is 2,000 shares. Retail investors are required to invest a minimum of ₹1,02,000, while the minimum investment for High-Net-Worth Individuals (HNIs) is 2 lots (4,000 shares), amounting to ₹2,04,000.

MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED is the book-running lead manager while BIGSHARE SERVICES PVT LTD is the registrar for the Issue. Pure Broking Private Limited is the Market Maker for Hamps Bio IPO.

 

Hamps Bio Limited IPO GMP Today
The Grey Market Premium of Hamps Bio Limited IPO is expected to be ₹43 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.

Hamps Bio Limited Day Wise IPO GMP Trend 

Date	IPO Price	Expected Listing Price	GMP	Last Updated
17 December 2024	₹ 51	₹ 94	₹ 43 (84.31%)	06:00 PM; 17 Dec 2024
16 December 2024	₹ 51	₹ 65	₹ 14 (27.45%)	05:30 PM; 16 Dec 2024
13 December 2024	₹ 51	₹ 65	₹ 14 (27.45%)	05:30 PM; 13 Dec 2024
12 December 2024	₹ 51	₹ 57	₹ 10 (19.60%)	06:00 PM; 12 Dec 2024

Hamps Bio Limited IPO Live Subscription Status Today: Real-Time Updates
As of 07:00 PM on 17 December 2024, the Hamps Bio IPO live subscription status shows that the IPO subscribed 1003.34 times on its Third day of subscription period. Check the Hamps Bio IPO Live Subscription Status Today at BSE.

Hamps Bio Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Hamps Bio IPO allotment date is 18 December, 2024, Wednesday. Hamps Bio IPO Allotment will be out on 18th December 2024 and will be live on Registrar Website from the allotment date. Check Hamps Bio IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Hamps Bio Limited IPO from the dropdown list of IPOs.
- Enter your application number, PAN, or DP Client ID.
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.

 

Objectives of Hamps Bio Limited IPO
Hamps Bio Issue Proceeds from the Fresh Issue will be utilized towards the following objects : 
1. ₹359.00 Lakh is required for Purchase of plant & machinery for FMCG division;
2. ₹50.00 Lakh is required for Enhancing the visibility and awareness of their brand;
3. ₹151.87 Lakh is required for General corporate purposes

Refer to Hamps Bio Limited RHP for more details about the Company.

Check latest IPO Review & analysis, Live IPO GMP today, Live IPO Subscription Status Today, Share Price, Financial Information and other details before applying in the IPO.

The Upcoming IPOs in this week and coming weeks are International Gemmological, Hamps Bio, NACDAC Infrastructure, Transrail Lighting, Identical Brain Studios, Rosmerta Digital, Indo Farm and Avanse Financial.

The Current active IPO is and Yash Highvoltage, Inventurus Knowledge, Sai Life Sciences, Mobikwik, Vishal Mega Mart, Supreme Facility, Purple United, Jungle Camps and Toss The Coin.

The Closed IPOs are  Dhanlaxmi Corp, Emerald Tyre Manufacturers, Nisus Finance, Ganesh Infraworld, Suraksha Diagnostic, Agarwal Toughened.

The Recently Listed IPOs which is available for trading in stock Market are Apex Ecotech, Rajputana Biodiesel, Rajesh Power Services, C2C Advanced System, Enviro Infra Engineers, Waaree Energies Limited IPO, Diffusion Engineers Limited IPO, KRN Heat Exchanger Limited IPO, P N Gadgil Jewellers Limited IPO, Bajaj Housing Finance Limited IPO, Gala Precision Engineering Limited IPO, Premier Energies Limited IPO, Orient Technologies Limited IPO, Interarch Building Products Limited IPO, Unicommerce eSolutions Limited IPO and many more.

Read more

About Hamps Bio Limited

Hamps Bio is engaged in the ethical marketing and distribution of pharmaceutical formulation products (“Pharma”) across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products (“FDFP” or “FMCG Division”) such as fruits, vegetables, herbs and flowers. They are recognized in the pharmaceutical industry under their own brand name “Hamps” and in freeze-dried and frozen food segment through their own brand “FzyEzy”. They sell their products through more than 50 distributor’s network as on October 31, 2024 and E-commerce platform, including Amazon.com, Amazon.ca, Amazon.eu, Flipkart, Jio Mart, Etc. They sell their pharma products primarily in 8 States and Union territories and our FDFP products primarily in 6 countries and 22 States and Union territories. As on the date of this Prospectus, they had a range of more than 180 different products sold across both the segments. 

Hamps Bio have total 78 employees by function as on October 31, 2024. The Banker to the Company are HDFC Bank Limited and Kotak Mahindra Bank Limited.

PHARMACEUTICLE INDUSTRY
India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 API producers that make for around 8% of the worldwide API market.

Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with a potential to steer the industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the "pharmacy of the world" due to the low cost and high quality of its medicines.

Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian Pharma ranks third in pharmaceutical production by volume. The Pharmaceutical industry in India is the third largest in the world in terms of volume and 14th largest in terms of value. The Pharma sector currently contributes to around 1.72% of the country’s GDP.

According to a recent EY FICCI report, as there has been a growing consensus over providing new innovative therapies to patients, Indian pharmaceutical market is estimated to touch US$ 130 billion in value by the end of 2030. Meanwhile, the global market size of pharmaceutical products is estimated to cross over the US$ 1 trillion mark in 2023.

Market size of India pharmaceuticals industry is expected to reach US$ 65 billion by 2024, and ~US$ 130 billion by 2030. According to the government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India.

India is among the top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in Asia Pacific. In 2022, India’s Biotechnology industry crossed US$ 80.12 billion, growing 14% from the previous year.During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market.

The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability, and innovation. The biosimilars market in India is estimated to grow at a compounded annual growth rate (CAGR) of 22% to become US$ 12 billion by 2025. This would represent almost 20% of the total pharmaceutical market in India. India is the 3rd largest producer of API accounting for an 8% share of the Global API Industry. About 500+ different APIs are manufactured in India, and it contributes 57% of APIs to prequalified list of the WHO. The current market size of the medical devices sector in India is estimated to be US$ 11 billion and its share in the global medical device market is estimated to be 1.5%. The domestic pharmaceutical sector expects sales to grow 8-10% in the financial year 2023-24, indicated an analysis done by CRISIL, a global analytical research and rating agency.

Indian pharma companies have a substantial share in the prescription market in the US and EU. The largest number of FDA-approved plants outside the US is in India. According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade. India’s domestic pharmaceutical market stood at US$ 42 billion in 2021 and is likely to reach US$ 65 billion by 2024 and further expand to reach US$ 120-130 billion by 2030. India's biotechnology industry comprises biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics. The Indian biotechnology industry was valued at US$ 70.2 billion in 2020 and is expected to reach US$ 150 billion by 2025. India’s medical devices market stood at US$ 10.36 billion in FY20. The market is expected to increase at a CAGR of 37% from 2020 to 2025 to reach US$ 50 billion. As of August 2021, CARE Ratings expect India's pharmaceutical business to develop at an annual rate of ~11% over the next two years to reach more than US$ 60 billion in value.

In the global pharmaceuticals sector, India is a significant and rising player. India is the world's largest supplier of generic medications, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand. The Indian pharmaceutical sector is worth US$ 42 billion worldwide. In August 2021, the Indian pharmaceutical market increased at 17.7% annually, up from 13.7% in July 2020. According to India Ratings & Research, the Indian pharmaceutical market revenue is expected to be over 12% Y-o-Y in FY22.

Pharmaceutical is one of the top ten attractive sectors for foreign investment in India. The pharmaceutical exports from India reach more than 200 nations around the world, including highly regulated markets of the USA, West Europe, Japan, and Australia. India supplied around 45 tonnes and 400 million tablets of hydroxychloroquine to around 114 countries globally.

India’s drugs and pharmaceuticals exports stood at Rs. 2,08,231 crore (US$ 25.3 billion) for FY23, as per the data by Pharmexcil. Exports of drugs and pharmaceuticals recorded a positive growth of 8.14% between April-October 2023. Exports of Drugs & Pharmaceuticals was estimated to be at US$ 2.42 billion in October 2023 and shared 7.21% of the total exports of the month.

India is the 12th largest exporter of medical goods in the world. Indian drugs are exported to more than 200 countries in the world, with US being the key market. Generic drugs account for 20% of the global export in terms of volume, making the country the largest provider of generic medicines globally. Indian drug & pharmaceutical exports stood at US$ 24.60 billion in FY22 and US$ 24.44 billion in FY21. Indian drug & pharmaceutical exports stood at US$ 2.19 billion in September 2022.

The pharmaceutical industry in India is a significant part of the nation's foreign trade and offers lucrative potential for investors. Millions of people around the world receive affordable and inexpensive generic medications from India, which also runs a sizable number of plants that adhere to Good Manufacturing Practices (GMP) standards set by the World Health Organization (WHO) and the United States Food and Drug Administration (USFDA). Among nations that produce pharmaceuticals, India has long held the top spot. Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending. Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers, which are on the rise. The Indian Government has taken many steps to reduce costs and bring down healthcare expenses. The National Health Protection Scheme, which aims to offer universal healthcare, the ageing population, the rise in chronic diseases, and other government programmes, including the opening of pharmacies that offer inexpensive generic medications, should all contribute to boost the Indian pharmaceutical industry. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.

FMCG SECTOR
The FMCG sector in India expanded due to consumer-driven growth and higher product prices, especially for essential goods. FMCG sector provides employment to around 3 million people accounting for approximately 5% of the total factory employment in India. FMCG sales in the country was expected to grow 7-9% by revenues in 2022-23. The key growth drivers for the sector include favourable Government initiatives & policies, a growing rural market and youth population, new branded products, and growth of e-commerce platforms. Resilience needs to be the key factor in the manufacturing process, daily operations, retail and logistic channels, consumer insights and communication that will help FMCG companies to withstand the test of time and create more value for consumers in the long run. India’s fast-moving consumer goods (FMCG) sector grew 7.5% by volumes in the April-June 2023 quarter, the highest in the last eight quarters, led by a revival in rural India and higher growth in modern trade.

Fast-moving consumer goods (FMCG) sector is India’s fourth-largest sector and has been expanding at a healthy rate over the years because of rising disposable income, a rising youth population, and rising brand awareness among consumers. With household and personal care accounting for 50% of FMCG sales in India, the industry is an important contributor to India’s GDP.

India is a country that no FMCG player can afford to ignore due to its middle-class population which is larger than the total population of USA. The Indian FMCG market continues to rise as more people start to move up the economic ladder and the benefits of economic progress become accessible to the public. More crucially, with a median age of just 27, India's population is becoming more consumerist due to rising ambitions. This has been further aided by government initiatives to increase financial inclusion and establish social safety nets.

Growing awareness, easier access and changing lifestyles have been the key growth drivers for the sector. The urban segment (accounts for a revenue share of around 65%) is the largest contributor to the overall revenue generated by the FMCG sector in India. However, in the last few years, the FMCG market has grown at a faster pace in rural India compared to urban India. Semi-urban and rural segments are growing at a rapid pace and FMCG products account for 50% of the total rural spending.

FMCG market reached US$ 167 billion as of 2023. Total revenue of FMCG market is expected to grow at a CAGR of 27.9% through 2021-27, reaching nearly US$ 615.87 billion. In 2022, urban segment contributed 65% whereas rural India contributed more than 35% to the overall annual FMCG sales. Good harvest, government spending expected to aid rural demand recovery in FY24. The sector had grown 8.5% in revenues and 2.5% in volumes last fiscal year. In the January-June period of 2022, the sector witnessed value growth of about 8.4% on account of price hikes due to inflationary pressures. In Q2, 2022, the FMCG sector clocked a value growth of 10.9% Y-o-Y higher than the 6% Y-o-Y value growth seen in Q1.

Indian food processing market size reached US$ 307.2 billion in 2022 and is expected to reach US$ 547.3 billion by 2028, exhibiting a growth rate (CAGR) of 9.5% during 2023-2028.

The Union government approved a new PLI scheme for the food processing sector, with a budget outlay of Rs. 109 billion (US$ 1.46 billion). Incentives under the scheme will be disbursed for six years to 2026-27. Digital advertising will grow to reach US$ 9.92 billion by 2023, with FMCG industry being the biggest contributor at 42% share of the total digital spend.

India includes 780 million internet users, where an average Indian person spends around 7.3 hours per day on their smartphone, one of the highest in the world. Number of active internet users in India will increase to 900 million by 2025 from 759 million in 2022. In 2021, India’s consumer spending was US$ 1,891.90 billion. Indian villages, which contribute more than 35% to overall annual FMCG sales, are crucial for overall revival of the sector. E-commerce now accounts for 17% of the overall FMCG consumption among evolved buyers, who are affluent and make average spends of about Rs. 5,620 (US$ 68).

The Indian e-commerce market is anticipated to grow from US$ 83 billion in 2022 to US$ 185 billion in 2026. By 2030, it is expected to have an annual gross merchandise value of US$ 350 billion. Fuelling e-commerce growth, India is expected to have over 907 million internet users by 2023, which accounts for ~64% of the total population of the country.

The market has grown exponentially over the past five years due to the surge in internet and smartphone users, improved policy reforms, and increase in disposable income. Mobile wallets, Internet banking, and debit/credit cards have become popular among customers for making transactions on e-commerce platforms. As of 2021, there were 1.2 million daily e-commerce transactions. The total value of digital transactions stood at US$ 300 billion in 2021 and is projected to reach US$ 1 trillion by 2026.

The FMCG market in India is expected to increase at a CAGR of 14.9% to reach US$ 220 billion by 2025, from US$ 110 billion in 2020. The Indian FMCG industry grew by 16% in CY21 a 9- year high, despite nationwide lockdowns, supported by consumption-led growth and value expansion from higher product prices, particularly for staples. The Indian processed food market is projected to expand to US$ 470 billion by 2025, up from US$ 263 billion in 2019-20.

Rural consumption has increased, led by a combination of increasing income and higher aspiration levels. There is an increased demand for branded products in rural India. On the other hand, with the share of the unorganised market in the FMCG sector falling, the organised sector growth is expected to rise with an increased level of brand consciousness, augmented by the growth in modern retail. Another major factor propelling the demand for food services in India is the growing youth population, primarily in urban regions. India has a large base of young consumers who form most of the workforce, and due to time constraints, barely get time for cooking. Online portals are expected to play a key role for companies trying to enter the hinterlands. The Internet has contributed in a big way, facilitating a cheaper and more convenient mode to increase a company’s reach. The number of internet users in India is likely to reach 1 billion by 2025. It is estimated that 40% of all FMCG consumption in India will be made online by 2020. E-commerce share of total FMCG sales is expected to increase by 11% by 2030. It is estimated that India will gain US$ 15 billion a year by implementing GST. GST and demonetisation are expected to drive demand, both in the rural and urban areas and economic growth in a structured manner in the long term and improved the performance of companies within the sector.

HAMPS BIO LIMITED COMPETITIVE STRENGTHS
1. Expert Leadership and Industry Experience driving Strategic Business Growth
2. Distribution Network with Expansive E-Retailing Presence
3. Wide and diversified range of products
4. Diversified, global customer base with long standing relationships
5. Wide Geographical Presence

HAMPS BIO LIMITED GROWTH STRATEGIES
1. Capital Expenditure to meet the growing demand of FDFP products
2. Increasing their Domestic and Global presence
3. Enhancing their Branding
4. Reduction of operational costs and achieving efficiency
5. Strengthen Marketing Network
6. To adopt Green Energy for procuring power
7. Improving Functional Efficiency

HAMPS BIO LIMITED RISK FACTORS & CONCERNS
1. They  don't have their own manufacturing facility for pharmaceutical products. 
2. Their existing manufacturing facility for freeze dried and frozen products is concentrated in a single region i.e., Ankelshwar, Gujarat.
3. They dependent upon few suppliers for the material requirements of their Freeze dried and Frozen Products business. 
4. They depend on the success of their relationships with their customers in their FMCG segment.